MétaCan
Menu
Back to cohort
Record W2750756186 · doi:10.1093/brain/awx185

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response

2017· article· en· W2750756186 on OpenAlexafffund
Tomáš Kalinčík, Ali Manouchehrinia, Lukáš Sobíšek, Vilija Jokubaitis, Tim Spelman, Dana Horáková, Eva Havrdová, María Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Marc Girard, Alexandre Prat, Pierre Duquette, Pierre Grammond, Patrizia Sola, Raymond Hupperts, François Grand’Maison, Eugenio Pucci, Cavit Boz, Raed Alroughani, Vincent Van Pesch, Jeannette Lechner‐Scott, Murat Terzi, Roberto Bergamaschi, Gerardo Iuliano, Franco Granella, Daniele Spitaleri, Vahid Shaygannejad, Celia Oreja‐Guevara, Mark Slee, Radek Ampapa, Freek Verheul, Pamela McCombe, Javier Olascoaga, Maria Pia Amato, Steve Vucic, Suzanne Hodgkinson, Cristina Ramo‐Tello, Shlomo Flechter, Edgardo Cristiano, Csilla Rózsa, Fraser Moore, José Luis Sánchez-Menoyo, Maria Luisa Saladino, Michael Barnett, Jan Hillert, Helmut Butzkueven

Bibliographic record

VenueBrain · 2017
Typearticle
Languageen
FieldMedicine
TopicMultiple Sclerosis Research Studies
Canadian institutionsJewish General HospitalCentre intégré de santé et de services sociaux de Chaudière-AppalachesUniversité de MontréalHôpital Notre-Dame
FundersNational Health and Medical Research CouncilSanofi GenzymeNovartis PharmaEMD SeronoH. Lundbeck A/SMultiple Sclerosis SocietyMultiple Sclerosis Society of CanadaCanadian Institutes of Health ResearchTeva Pharmaceutical IndustriesFondazione Italiana Sclerosi MultiplaMedical Research CouncilBiogenSanofi
KeywordsNatalizumabFingolimodMedicineCohortDiscontinuationDiseaseMultiple sclerosisExternal validityProportional hazards modelCohort studyPhysical therapyClinical trialInternal medicineOncologyPsychologyPsychiatry

Abstract

fetched live from OpenAlex

Timely initiation of effective therapy is crucial for preventing disability in multiple sclerosis; however, treatment response varies greatly among patients. Comprehensive predictive models of individual treatment response are lacking. Our aims were: (i) to develop predictive algorithms for individual treatment response using demographic, clinical and paraclinical predictors in patients with multiple sclerosis; and (ii) to evaluate accuracy, and internal and external validity of these algorithms. This study evaluated 27 demographic, clinical and paraclinical predictors of individual response to seven disease-modifying therapies in MSBase, a large global cohort study. Treatment response was analysed separately for disability progression, disability regression, relapse frequency, conversion to secondary progressive disease, change in the cumulative disease burden, and the probability of treatment discontinuation. Multivariable survival and generalized linear models were used, together with the principal component analysis to reduce model dimensionality and prevent overparameterization. Accuracy of the individual prediction was tested and its internal validity was evaluated in a separate, non-overlapping cohort. External validity was evaluated in a geographically distinct cohort, the Swedish Multiple Sclerosis Registry. In the training cohort (n = 8513), the most prominent modifiers of treatment response comprised age, disease duration, disease course, previous relapse activity, disability, predominant relapse phenotype and previous therapy. Importantly, the magnitude and direction of the associations varied among therapies and disease outcomes. Higher probability of disability progression during treatment with injectable therapies was predominantly associated with a greater disability at treatment start and the previous therapy. For fingolimod, natalizumab or mitoxantrone, it was mainly associated with lower pretreatment relapse activity. The probability of disability regression was predominantly associated with pre-baseline disability, therapy and relapse activity. Relapse incidence was associated with pretreatment relapse activity, age and relapsing disease course, with the strength of these associations varying among therapies. Accuracy and internal validity (n = 1196) of the resulting predictive models was high (>80%) for relapse incidence during the first year and for disability outcomes, moderate for relapse incidence in Years 2-4 and for the change in the cumulative disease burden, and low for conversion to secondary progressive disease and treatment discontinuation. External validation showed similar results, demonstrating high external validity for disability and relapse outcomes, moderate external validity for cumulative disease burden and low external validity for conversion to secondary progressive disease and treatment discontinuation. We conclude that demographic, clinical and paraclinical information helps predict individual response to disease-modifying therapies at the time of their commencement.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.004
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.835
Threshold uncertainty score0.503

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.004
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.231
GPT teacher head0.381
Teacher spread0.150 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations149
Published2017
Admission routes2
Has abstractyes

Explore more

Same venueBrainSame topicMultiple Sclerosis Research StudiesFrench-language works237,207